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Background: Data from in vivo and in vitro studies suggest that activation of Akt regulates cell survival signaling
and plays a key role in tumorigenesis. Hence, transgenic mice were created to explore the oncogenic role of Akt1
in the development of mammary tumors.
Methods: The transgenic mice were generated by expressing myristoylated-Akt1 (myr-Akt1) under the control of the
MMTV-LTR promoter. The carcinogen 7, 12 dimethyl-1,2-benzanthracene (DMBA) was used to induce tumor formation.
Results: The MMTV driven myr-Akt1 transgene expression was detected primarily in the mammary glands, uterus,
and ovaries. The expression level increased significantly in lactating mice, suggesting that the response was
hormone dependent. The total Akt expression level in the mammary gland was also higher in the lactating mice.
Interestingly, the expression of MMTVmyr-Akt1 in the ovaries of the transgenic mice caused significant increase in
circulating estrogen levels, even at the post-lactation stage. Expression of myr-Akt1 in mammary glands alone did
not increase the frequency of tumor formation. However, there was an increased susceptibility of forming
mammary tumors induced by DMBA in the transgenic mice, especially in mice post-lactation. Within 34 weeks,
DMBA induced mammary tumors in 42.9% of transgenic mice post-lactation, but not in wild-type mice
post-lactation. The myr-Akt1 mammary tumors induced by DMBA had increased phosphorylated-Akt1 and showed
strong expression of estrogen receptor (ERα) and epidermal growth factor receptor (EGFR). In addition, Cyclin D1
was more frequently up-regulated in mammary tumors from transgenic mice compared to tumors from wild-type
mice. Overexpression of Cyclin D1, however, was not completely dependent on activated Akt1. Interestingly,
mammary tumors that had metastasized to secondary sites had increased expression of Twist and Slug, but low
expression of Cyclin D1.
Conclusions: In summary, the MMTVmyr-Akt1 transgenic mouse model could be useful to study mechanisms of
ER-positive breast tumor development.
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The serine/threonine kinase Akt, also known as Protein
Kinase B (PKB) plays a key role in multiple cellular pro-
cesses. To date, three human isoforms of Akt have been
identified: Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ [1].
Akt1 has been shown to play a key role in cellular survival
pathways by inhibiting apoptotic processes, inducing cell* Correspondence: jayvadgama@cdrewu.edu
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unless otherwise stated.proliferation, and protein synthesis [1-3]. The PKB/Akt
pathway can be activated by a variety of growth factors,
hormones, and cytokines [4,5] and can participate in
oncogenic transformation of mammalian cells through
its regulation of key biological process [6,7]. Akt is fre-
quently constitutively active in many types of human
cancers, such as breast, ovarian, and prostate [8-10]. It
has been demonstrated by our group and others that
activated Akt1 in tumor cells are associated with high
grade tumors, late stage of diagnosis, and poor outcome
in patients [9,10]. Cell lines derived from breast cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have also shown upregulation of Akt [11]. Furthermore,
patients who have poor outcome and resistance to endo-
crine therapy have also been found to have activated Akt1
in their tumor cells [9]. We have recently demonstrated
that activation of Akt1 in breast tumor cells in vitro, leads
to inactivation of FOXO1 and a decrease in response or
resistance to trastuzumab-induced growth inhibition in
HER2 overexpressing breast cancer cells [12]. Significant
data from in vivo and in vitro studies suggest that activa-
tion of Akt regulates cell survival signaling and plays a key
role in tumorigenesis. Although a few in vivo studies have
explored the role of Akt in normal mammary develop-
ment and tumorigenesis using transgenic mouse models
[13-16], the mechanisms associated with the oncogenic
role of Akt remains to be further elucidated.
In this study, a transgenic mouse model with activated
Akt was developed, such that the in vivo mechanisms by
which Akt induces tumor development and progression
in the mammary gland can be better understood. This
transgene model also explores the mechanisms by which
a carcinogen, DMBA, may further enhance the induction
of Akt1 driven mammary gland tumors in virgin and
post-lactation mice. In addition, this MMTVmyr-Akt1
transgenic model could serve as a preclinical model for
studying ER-positive breast cancers that become resistant
to endocrine therapy and develop into metastatic disease.
Specifically, this model could be used to develop novel
target therapies in breast cancer research and treatment.
Methods
This study was approved by Institutional Animal Care and
Use Committee (IACUC) at Charles R. Drew University of
Medicine and Science.
Generation of transgenic mice
The DNA structures of constitutively active Akt1
(myr-Akt1) (#21-151) were obtained from the Upstate
Biotechnology Company. The activation of Akt1 was
accomplished by the presence of the 11 N-terminal
amino acids of avian c-src that were required for protein
myristoylation at the amino terminus of Akt1. The pro-
moter in the original myr-Akt1 DNA structure (#21-151,
Upstate Biotechnology) was a human cytomegalovirus
immediate-early promoter (CMV). To create a mammary
tissue specific mouse transgene, the CMV promoter was
replaced by the MMTV-LTR (American Type Culture
Collection). The MMTV-LTR promoter was inserted into
plasmid DNA containing myr-Akt1 sequences (Additional
file 1: Figure S1A). The construct was digested and the
fragments containing the MMTV-LTR promoter, myr-
Akt1 sequences, and SV40 polyadenylation signal were
isolated and purified (Additional file 1: Figure S1B). The
transgenic mice were generated by microinjection ofDNA directly into one of the pronuclei of C57BL/6
mouse-fertilized zygotes at the University of California,
at Los Angeles (UCLA) transgenic facility. The genotyping
of the transgenic MMTVmyr-Akt1 mice was performed
by polymerase chain reaction (PCR) with genomic DNA
extracted from the tails of mice. Integration of the trans-
gene and the transgene copy number were determined by
real-time quantitative PCR [17,18]. The standard curve
was generated by mixing non-transgenic tail DNA with
transgene plasmid DNA. The single copy transgene was
determined using the calculation method provided by
the University of Michigan Transgenic Animal Model
Core facility available at http://www.med.umich.edu/tamc.
An example of the copy number standard curve is shown
in Additional file 1: Figure S1C. The Ct numbers from the
genomic DNA of positive transgenic and wild-type (WT)
litters were filled into a linear regression model and the
copy number of transgenes was estimated. As shown in
Additional file 1: Figure S1D, myr-Akt1+/+was defined as
mice with 2 copy numbers of the transgene, such as mice
2-11 and 2-23. Myr-Akt1+/- was defined as mice with 1
copy number of the transgene, such as mice 2-10, 2-12,
and 2-33. Mice 2-14 and 2-21 were transgene negative.
DMBA Treatment
The carcinogen 7, 12 dimethyl-1,2-benzanthracene (DMBA,
Sigma) was dissolved in olive oil at a concentration of
10 mg/ml. This mixture was heated at 37°C and shaken
vigorously to fully dissolve the DMBA. Virgin and post-
lactation female transgenic (MMTVmyr-Akt1+) and wild-
type (WT) mice were treated with 1 mg doses of DMBA
via oral gavage weekly for a total of 6 weeks. Mice were
maintained in the absence of males and were checked
by palpation for tumor formation after completion of
the DMBA treatments. The mice were sacrificed by CO2
inhalation either when tumors reached 225 mm2 or if
the mice became moribund either during or at the end
of the 34 week observation period. As indicated before,
this study was approved by Institutional Animal Care and
Use Committee (IACUC) at Charles R. Drew University of
Medicine and Science.
Histopathology and immunohistochemistry (IHC)
The mammary glands, tumor tissues, and other organs
from the mice were formalin-fixed and embedded in
paraffin. The tissue sections were stained with either
hematoxylin and eosin (H&E) or underwent immuno-
histochemistry (IHC) with specific antibodies. The anti-
bodies used were as follows: anti-phospho-Akt1(ser473)
(Cell Signaling, MA), anti-pan-keratins (pan-CKs), anti-
ERα, anti-EGFR (Santa Cruz Biotechnology, CA), and
anti-ERBB2 (Vector Laboratories, Inc, CA). The dilution
of each antibody was according to the manufactures’
instructions, and positive staining was detected using
Wu et al. BMC Cancer 2014, 14:266 Page 3 of 13
http://www.biomedcentral.com/1471-2407/14/266diaminobenzidene (DAB) (Vector Lab, CA) according
to the manufacturer's instructions. The data was inde-
pendently reviewed by two pathologists.
Reverse transcription-PCR (RT-PCR) and quantitative
real-time PCR (Q-PCR)
The total RNA from tumor tissues or organs was isolated
using the RNeasy micro kit (#74004, QIAGEN) according
to the manufacturer’s instructions. Subsequently, cDNA
was synthesized by reverse transcription (RT) with Ther-
moScript™ RT-PCR system (Invitrogen) per the manufac-
turer’s instructions and followed by PCR. The primers
used were as follows: AKT: 5’TCCTCAAGAAGGAAGTC
ATCGT-3’ (forward) and 5’-CGTACTCCATGACAAAGC
AGAG3’ (reverse); myr-Akt1: 5’- ACCACTTGTCTCACA
TCCTTGTT -3’ (forward) and 5’TTCTAGACTTGGGCT
TGCTCTT-3’ (reverse); β-actin: 5’- GTCTTCCCCTCCA
TCGT-3’ (forward) and 5’- CGTACATGGCTGGGGTG
T-3’ (reverse). The PCR products were separated on 2%
agarose gels with ethidium bromide. The final results for
each gene were quantified using GelQuant.NET software
(BiocheLabSolution.com) and adjusted for β-actin. Q-PCR
analysis was performed with iCycle iQ real-time PCR de-
tection system (Bio-Rad Lab, Hercules, CA) using SYBR
Green Master Mix (#204143, QIAGEN). The primers used
were as follows: SLUG: 5- 5’-AGAGCATTTGCAGAC
AGGTCA-3’ (forward) and 5’AGCAGCCAGATTCCTCA
TGTT-3’ (reverse), 18S, 5'-GATCCATTGGAGGGCAAG
TC-3' (forward) and 5'-TCCCAAGATCCAACTACGAG-
3' (reverse). The mRNA levels of SLUG were quantified by
measuring the threshold cycle (Ct) and were adjusted for
the level of 18S.
Mammary gland whole mounts
Mammary glands near the hind legs were harvested
from WT and transgenic mice at the indicated times and
fixed in 10% formalin overnight. The fixed mammary
glands were then placed in 75% ethanol for 2 hours and
placed in acetone overnight at -20°C. The tissues were
then rehydrated with successive incubation with differ-
ent concentrations of ethanol, stained with hematoxylin
for 1.5 hours, and then rinsed in crude tap water over-
night. Tissues were then placed in 50% ethanol with
12 N of HCl for 30 minutes for destaining followed
again with successive incubation in graded ethanol for
dehydration. Subsequently, the tissues were incubated in
xylene, then mounted in Permount (Fisher Scientific).
Under 10x magnification, the total number of buds
(terminal end buds and alveoli buds) were counted and
divided by the total number of ducts as follows: pre-
puberty and pubertal mice 2-4 ducts, 12-week virgin
mice 7-11 ducts, 16-week and 26-week mice 11-17
ducts. Two mice per condition and per genotype were
used for analysis.Western blot analysis
The total protein from snap-frozen tumor tissues
were extracted by homogenization using the Powergen
Homogenizer 125 (Fisher Scientific) in 1 ml extraction
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% SDS and 10 μl Protease
Inhibitor Cocktail - Cat#78410, Thermo Scientific). Ho-
mogenates were centrifuged at 1000 g for 10 minutes at
4°C, and 80 μg of proteins for each sample were used
for Western Blot analysis. The following antibodies were
used: anti-phospho-Akt1 (ser473), anti-AKT, anti-Cyclin
D1 (Cell Signaling, MA); anti-ERα, anti-CK18, anti-Twist,
and anti-β-actin (Santa Cruz Biotechnology, CA).Measurement of estradiol levels
Blood was collected from both WT and transgenic mice
from each of the following conditions: 3 month-old virgin
mice, ~4 month-old lactating mice 3 days after giving
birth, and ~ 5 month-old post-lactating mice one month
after giving birth. The blood samples were collected im-
mediately after euthanization (two mice for each group).
Serum estradiol (E2) levels were measured by ELISA assay
(Cat# ES180S-100, Calbiotech Inc, CA) per the manu-
factures’ instructions. The E2 level was determined
based on the principle of competitive binding between
E2 in serum samples and E2 enzyme conjugate for a
constant amount of anti-estradiol antibody. The sensitivity
of the assay is <3 pg/ml.
Statistical analysis
Statistical analysis was performed with the SPSS statistical
package (Version 11.0 for windows, IBM). Kaplan-Meier
survival curve analysis with the log-rank test was used to
determine the tumor-free survival between transgenic and
wild-type mice treated with DMBA. The Spearman rank
test was used to examine the differential incidences of dif-
ferent tumors types between different groups of DMBA
treated mice. P-values < 0.05 were considered statistically
significant.
Results
MMTVmyr-Akt1 transgene expression in transgenic mice
To determine the organ specificity of MMTV driven
myr-Akt1 transgene expression, we extracted RNA from
different organs of the female mice at different ages. As
shown in Figure 1A, myr-Akt1 was detected in the
mammary glands, the uterus, the ovaries, and the heart
of virgin transgenic mice at 9 weeks old as well as post-
lactating transgenic mice at 16 weeks old. The data in
Figure 1B showed mRNA levels of myr-Akt1 expression
at different development stages of transgenic mice. The
mRNA level was detected in the mammary gland, but
































Quantified myr-Akt1 levels in MMTV-myr-Akt1+ mice






























Figure 1 Expression of activated Akt1 in transgenic mice at different development stages. (A) Total RNA was extracted from the indicated
organs of virgin (9 week old) and post-lactating (16 week old) transgenic mice. RT-PCR was performed with primers for myr-Akt1 and β-actin.
Three mice per genotype, per age group were used for analysis. Myr-Akt1 was detected in the lungs, heart, uterus, and mammary glands of the
virgin and post-lactating mice. (B) The mRNA levels of myr-Akt1 were quantified in different organs of the transgenic mice at different
developmental states. Myr-Akt1 levels were adjusted for the levels of β-actin. Data are presented as bar graphs. The bars indicate mean levels and
SD from three mice and “*” indicates p < 0.05 compared to the virgin mice. (C) H&E staining (a and b), and immunohistochemical detection of
phospho-Akt1 (ser743) (c and d) in the mammary glands of wild-type mice (WT) and transgenic mice (MMTVmyr-Akt1).
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of transgenic mice significantly increased in the lactating
stage 3 days after giving birth and decreased at the post-
lactation stage one month after giving birth. The myr-
Akt1 expression in the lungs, the heart, the uterus and
the ovaries began to be detected at 9 weeks in the virgin
transgenic mice. The myr-Akt1 in the uterus and ovaries
were also significantly increased during pregnancy and
lactation (Figure 1B). In contrast, myr-Akt1 was un-
detectable in WT mice in the same organs, at varying
ages, and lactation stages (data not shown). The myr-
Akt1 dominant phenotype in the virgin transgenic mice
was exhibited until 12 weeks. A clear increase in the
phosphorylation of Akt1 at ser473 (pAkt1) was detected
by IHC analysis in the mammary glands of 12-week-old
virgin female transgenic mice, but not in the young 4-
week-old virgin transgenic mice (Figure 1C). Neither the
12 week-old nor the 4-week-old WT mice had pAktexpression in their mammary glands. In addition, the
serum estradiol (E2) levels in the transgenic mice were sig-
nificantly higher during the lactating stage and remained
higher even in the post-lactation stage compared to WT
mice (Figure 2A). The levels of Akt1 expression followed a
similar trend as E2 expression during the lactating stage
(Figure 2B). Interestingly, the total AKT levels in the
mammary glands of the virgin transgenic mice at 5 weeks
old, at 9 weeks old, and during lactation were significantly
higher compared to WT mice at the same mammary
development stages. The total AKT levels in the liver,
the lungs, the ovaries, and the uterus of the WT and
MMTVmyr-Akt1+ mice also increased significantly
during the multiparous/lactation period and decreased
at the post-lactation stage a month later after birth
(Figure 2C). Overall, transgenic mice had higher total
AKT expression in their organs compared to WT mice
(Figure 2C and Additional file 2: Figure S2).
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*p<0.05 compared to virgin
Figure 2 Estradiol level and total AKT expression in wild-type (WT) and transgenic mice. (A) Blood samples were collected from virgin,
lactating, and post-lactating mice and serum estradiol levels were measured by ELISA assay according to the manufacturer’s instructions. The line
graph indicates trend of estradiol levels (mean of seven samples plus SD) in WT (n = 21) and transgenic mice (n = 21) from virgin to post-lactating
stage. (B) RNA was collected from the mammary glands of WT and transgenic mice and RT-PCR was performed with AKT primers and quantified
with β-actin. The lines indicate the trends of mean levels of total AKT adjusted for β-actin in the mammary glands of WT (n = 9) and transgenic
mice (n = 9) at pre-puberty virgin (5 weeks olde, n = 3), puberty virgin (9 weeks olde, n = 3), lactating (14 weeks old, n = 3) and post-lactating
(16 weeks old, n = 3) stages. (C) mRNA levels of total AKT from different organs in WT (top) and transgenic mice (bottom) at indicated stages
were determined by RT-PCR. The mean total AKT levels are adjusted for β-actin was shown in the bar graphs. Each bar indicates mean and SD
from four mice. Each sample was triplicated and “*” indicates p < 0.05 compared to virgin.
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mary gland growth, whole mounts of mammary glands
from different ages and stages of transgenic mice were
compared to WT mice at the same ages and stages. The
assessment compared mice at the pre-pubertal stage
(10 day old pups), pubertal stage (3 week old virgins),
post-pubertal stage (12 week old virgins), and among the
post-lactation stage (16 week old, 2 weeks after weaning
and 26 week old, 12 weeks after weaning). The mam-
mary structure and cellular composition were similar be-
tween younger virgin MMTVmyr-Akt1+ mice and WT
mice. Differences included fewer ducts with end buds
(characterized as conspicuous club-shaped structures)
[18] growing from fewer terminal branches (Figure 3Aa,
3Ab and 3Af, 3Ag). A significant difference was observed
in 12 week old virgin mice group. The mammary glands
from the MMTVmyr-Akt1+ mice showed a marked in-
crease in the number of terminal branches and terminalend buds (TEB) compared to WT mice (Figure 3Ac and
3Ah). It is well known that the alveolar epithelium ex-
pands during pregnancy and undergoes apoptosis and
remodeling during involution [19]. However, the alveoli
buds which are smaller and hollow cavities, were ob-
served in the mammary glands of the MMTVmyr-Akt1+
mice 2 weeks after weaning, but not in the WT mice
(Figure 3Ad and 3Ai). Even after 3 months of weaning,
there were still fewer alveoli structures in the MMTVmyr-
Akt1+ mice (Figure 3Ae-3Aj and 3B). These data indicate
a delayed involution due to the activation of Akt. In
addition, the number of terminal end buds and alveoli
buds in the mammary glands were quantified throughout
development. Figure 3C demonstrates that the number of
total buds were slightly more in the MMTVmyr-Akt1+
mice than in the WT mice. There were no statistically
significant differences among the 10 day old and 3 week
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CB Enlarged example of mammary gland from 26- week old Myr-Akt1+




16-week old 26-week old
Figure 3 Effect of myr-Akt1 in mammary gland development. Representative whole mounts of WT (Aa to Ae) and myr-Akt1+ (Af to Aj)
mammary glands at the indicated ages and stages. Black arrows indicate ducts. Blue arrows indicate side branches and green arrows indicate
terminal end bubs (TEB). (B) An enlarged example of duct and alveolar buds from mammary glands of 26 week old myr-Akt1+ mice (12 weeks
after weaning). (C) Quantification of the average number of buds per duct in the indicated ages and stages of WT and myr-Akt1+ mice. The
numbers of bubs were counted and divided by the total number of ducts in the fields. Five fields per mouse were counted in the 12 week, 16 week
and 26 week age groups. Two mice per age group and per genotype were used for analysis. The data represented in line plot is mean ± SD
and “*” indicates p < 0.05 compared to WT mice at same age.
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period. The total numbers of buds were significantly more
in the MMTVmyr-Akt1+ mice at 12 weeks old compared
to the WT mice (Figure 3C).
Reproduction and survival rate of mice carrying myr-Akt1
transgene
The survival rate of litters was similar between trans-
genic and WT mice (Table 1). Comparing to litters from
MMTVmyr-Akt1+/- parents, the survival rate was slightly
higher in litters from MMTVmyrAkt1+/+parents (96% vs.
88%). The average babies per litter were also similar
among the transgenic and the WT mice (Table 1). In
addition, the body weight was slightly higher in the
transgenic mice compared to the WT mice (Additional
file 3: Figure S3).Development and pathology of tumors induced by DMBA
in MMTVmyr-Akt1 mice
Previous studies have shown that AKT1 transgenic mice
expressing constitutively active Akt1 have delayed mam-
mary gland involution, but do not exhibit neoplasia
[13,14]. Formation of mammary neoplasms requires
induction by a carcinogen. In this study, 28 mice (14
MMTVmyr-Akt1+ and 14 WT) were followed until
18 months of age. No spontaneous malignant neoplasms
were observed in the mammary glands or the other organs
of mice with and without the MMTVmyr-Akt1 transgene
(data not shown). The transgenic and WT female mice at
the virgin stage and at post-lactation a month after giving
birth were fed by oral gavage with 1 mg doses of DMBA
once a week for 6 consecutive weeks. The ages of virgin
mice were between 14 to16 weeks old, and between 20 to
Table 1 Survival rates of information of transgenic mice

















F1 - - - 88 7 (4-8) 57 78 9
F2 100 8 (7-9) 61 96 7 (6-7) 35 - -
F3 100 5 (3-7) 53 90 6 (3-9) 43 100 7
F4 97 6 (3-8) 57 88 8 14 95 6 (5-8)
F5 100 7 (4-9) 31 68 7 (2-8) 53 - -
F6 95 7 (6-10) 29 96 8 (6-9) 37 100 8 (6-9)
F7 94 6 (2-9) 37 94 7 (2-9) 27 95 7 (4-8)
F8 88 8 (7-9) 36 82 7 (3-10) 22 100 7 (6-7)
Average 96 7 (2-10) 88 7 (2-10) 95 7 (5-9)
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quence of DMBA treatments is shown in Figure 4A. The
earliest tumors were detected 12 weeks after the comple-
tion of DMBA treatment. Figure 4B shows an example of
tumor growth in the mammary glands of transgenic mice.
The oral DMBA treatment induced mammary tumors and
tumors in other organs as well. There were no significant
differences in the death rate between the WT and the
MMTVmyr-Akt1+ mice (Figure 4C). Overall, the inci-
dence of mammary gland malignant tumors and benign
masses were significantly higher in the MMTVmyr-Akt1+
mice in the WT mice (42.9% vs. 7.1%) as shown in
Figure 4D (left).
Detailed histopathological descriptions of the DMBA
induced tumors in WT and transgenic mice are shown in
Table 2. Overall 32.1% of the MMTVmyr-Akt1+ mice de-
veloped mammary carcinomas. Approximately 22% of the
myr-Akt1 driven mammary tumors induced by DMBA
were infiltrating poorly differentiated carcinomas and had
malignant bone lesions in the same mice. The malignant
bone lesions showed similar pathology as the mammary
carcinomas from the same mouse. The incidence of mam-
mary carcinomas in the MMTVmyr-Akt1+/+mice were
significantly higher than in the MMTVmyr-Akt1+/- mice
(35.3% vs. 27%, p < 0.05) (Figure 4D, right). The inci-
dence of benign mammary masses were higher in the
MMTVmyr-Akt1 +/- mice compared to MMTVmyr-
Akt1+/+mice. In addition, the MMTVmyr-Akt1 +/- mice
induced with DMBA also developed tumors at other sites.
Interestingly, DMBA induced mammary gland tumor for-
mation in virgin and post-lactating transgenic mice, but
not in post-lactating WT mice (Table 3). Table 3 demon-
strates that approximately 23.5% and 45.5% of mammary
gland malignant lesions were induced by DMBA in virgin
and post-lactating transgenic mice, respectively. DMBA
also induced salivary gland and lung carcinomas in WT
virgin mice. The benign mammary lesions also appeared
in MMTVmyr-Akt1+ mice treated with DMBA at virginand post-lactation stages, but did not appear in the WT
mice. In addition, DMBA treatment induced carcinomas
in the stomach and benign skin lesions in both the WT
and transgenic mice. The incidence of mammary gland
tumor formation in post-lactating transgenic mice was
concordant with relatively higher expression levels of pAkt
and total AKT in the mammary gland tissues as shown in
Figures 1 and 2. The expression of myr-Akt1 in the ovaries
of the transgenic mice may result in increased circulating
estrogen levels. There may be a feedback loop between
AKT pathway and estrogen pathway which is enhanced
during carcinogen-induced tumorigenesis.
Phenotype of mammary malignant tumors
The phenotype of the mammary tumor tissues from WT
and transgenic mice were further characterized and
distinctive differences were identified. The mammary
tumors from positive transgenic mice were more likely
to have activation of Akt1 and to be ER + and/or PR+,
HER2- and EGFR+. DMBA-induced mammary gland tu-
mors from WT mice were negative for pAkt expression
and expressed lower levels of ER and PR. EGFR expression
was moderately positive whereas HER2 expression was
negative. Positive Ki67 expression was identified in all the
mammary tumors from transgenic mice. Among the WT
mice, ~60% of tumors were positive for Ki67 (data not
shown). The tumors that had higher Ki67 expression were
more likely to be PR+. HER2 receptor expression was not
detected in any of the tumors (data not shown). The IHC
data in Figure 5A shows examples of protein expression
for pAkt1, ERα, and EGFR in tumors from the transgenic
(P1) and WT (N2) mice. The association between pAkt1
overexpression and increased nuclear expression of ERα
in mammary gland tumor from mouse-P1 is demonstrated
in Figure 5A. The malignant bone lesions from transgenic
mice, P1 and P3, were also correlated with ERα positive
tumors (data not shown). Moderate to high expression of
EGFR was observed in DMBA-induced mammary tumors
Table 2 Incidence and histopathological description of malignant and benign tumors induced by DMBA
^WT (N = 28) N (%)* ^^Myr-Akt1 + (N = 28) N (%)*
Infiltrating poorly differentiated mammary carcinoma with bone metastases 0 2 (7.1%)
Poorly differentiated mammary carcinoma with necrosis 2 (7.1%) 7 (25.0%)
Salivary gland carcinoma with bone metastasis 1 (3.6%) 0
Carcinoma in the wall of the stomach 1 (3.6%) 1 (3.6%)
Carcinoid pattern of malignancy in lung 1 (3.6%) 0
Benign lesions of mammary gland with lymploid tissue 0 3 (10.7%)
Endometrial cystic changes with focal hyperplasia 1 (3.6%) 0
Benign squamous epithelium tumor 1 (3.6%) 1 (3.6%)
^Wild-type mice.
^^MMTV-myr-Akt1 transgenic mice.












































































Figure 4 Tumor development in wild-type and MMTVmyr-Akt1 transgenic mice treated with DMBA. (A) Experimental design and scheme
of DMBA treatment. (B) Mammary gland tumor growth in transgenic mouse. (C) Tumor-free survival curves in wild-type and MMTVmyr-Akt1
transgenic mice, analyzed by Kaplan-Meier survival curve analysis with log-rank test. (D) Bar graphs indicate incidences of tumor formation in
wild-type (WT) and transgenic mice (MMTVmyr-Akt1) (left), and incidences of mammary gland tumors and other site tumors in transgenic mice
from MMTVmyr-Akt1 +/+and MMTVmyr-Akt1 +/-groups (right). At left, p = 0.009 indicates the significant differences in the incidence of mammary
tumor and other organ site tumor formation among WT and myr-Akt1 mice. At right, “*” indicates p < 0.05 between the indicated two groups
and "^" indicates p < 0.01 between the indicated two groups.
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Table 3 Incidence of malignant and benign tumors induced by DMBA
Wild-Type (N = 28) MMTV-myr-Akt1 + (N = 28)
Virgin (N = 17) Post-lactating (N = 11) Virgin (N = 17) Post-lactating (N = 11)
Mammary carcinoma 2 (11.8%) 0 4 (23.5%) 5 (45.5%)
Salivary gland carcinoma 1 (5.9%) 0 0 0
Stomach carcinoma 1 (5.9%) 0 0 1 (9.1%)
Malignancy in lung 1 (5.9%) 0 0 0
Benign mammary tumor 0 0 2 (11.8%) 1 (9.1)
Endometrial hyperplasia 1 (5.9%) 0 0 0
Benign skin tumor 1 (5.9%) 0 0 1 (9.1)
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EGFR expression was mainly in the cytoplasm of the
tumor tissues from transgenic mice and in the cell mem-
brane of the tumors from the WT mice (Figures 5A, d
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http://www.biomedcentral.com/1471-2407/14/266weak expression of ERα. The total AKT levels remained
similar in all tumors from transgenic and WT mice
(Figure 5B).
Cyclin D1 and EMT marker twist and slug expression in
mammary tumors from MMTVmyr-Akt1 mice
It is well known that active Akt1 induces cell proliferation.
Cyclin D1 is one of the key cell cycle regulators and has
been implicated in oncogenesis. In our model, Cyclin D1
expression levels varied in mammary tumors from trans-
genic mice but were overall lower in tumors from WT
mice (Figure 5C). However, the Cyclin D1 expression level
determined by western blot analysis did not fully correlate
with Ki67 expression as determined by IHC analysis (data
not shown). Data in Figure 5C shows increased AKT
and decreased PTEN mRNA levels in tumors from mice
carrying the myr-Akt1 transgene.
Furthermore, the EMT markers, twist and slug, were
up-regulated by the myr-Akt1 transgene. Previous studies
have shown that increased invasiveness and motility are
correlated with the mesenchymal phenotype [20]. In our
model, mice which carried the myr-Akt1 had higher slug
and twist expression in the mammary tumors and were
more likely to have tumors with invasive and metastatic
characteristics. Evaluation of tumor pathology revealed
that the mammary tumors from the transgenic mice, P1
and P3, were poorly differentiated infiltrating carcinomas
with bone metastases. Concordantly, twist (Figure 5B) and
slug (Figure 5D) were highly expressed in the tumors from
P1 and P3. The WT mouse, N7, had a poorly differenti-
ated mammary carcinoma and carcinoid pattern of ma-
lignancy in the lung. These malignant lesions also had
increased twist expression as well as relatively higher
expression level of slug (Figure 5C and 5D). Pan-CKs
and CK18 expression was also evaluated in these mam-
mary tumors. The epithelial marker, CK18, protein level
expression was significantly high in all mammary tu-
mors from transgenic and WT mice (Figure 5B). The
benign mammary masses also expressed CK18 protein
but the levels were lower compared to the malignant
mammary tumors (data not shown). The overall pan-
CK expression was also higher in malignant mammary
tumors from transgenic mice than tumors from WT
mice (data not shown).
Discussion
The goal of this study was to examine the oncogenic role
of Akt in the development of mammary tumors. Myristoy-
lation of Akt is a well-accepted mechanism to produce
constitutively activated Akt in cells. Hence, we selected an
established DNA structure of constitutively active Akt1
(myr-Akt1) that was generated by Upstate Biotechnology
and tested in vitro in our previous study [12]. Myr-Akt1
was driven by MMTV-LTR to target the expression of thetransgene specifically to the mammary gland tissue. Simi-
lar strategies have been used by other groups to develop
Akt1-transgenic mouse models [13,15].
The myr-Akt1 transgene was expressed most signifi-
cantly in the mice mammary glands in our model. This
is consistent with the findings that there is an increase
in the MMTV-LTR transcriptional activity throughout
mammary development and during pregnancy [21]. In-
creased phosphorylation of Akt at ser473 was detected in
the mammary glands of 9 week old transgenic mice in the
model developed by Blanco-Aparicio and colleagues [15].
Similarly, we detected phosphorylated Akt at ser473 in
our transgenic mice at 12 weeks old. Myr-Akt1 was also
detected in the brain, salivary glands, ovaries, and uterus
in the model developed by Blano-Aparicio group. We also
found expression of myr-Akt1 in the ovaries and uterus of
our transgenic mice. We did not examine expression in
the brain or salivary glands in our study. In addition, the
mRNA level of total AKT was higher in most organs from
our transgenic mice compared to wild-type mice exam-
ined at pre-puberty, puberty, during lactation, and at post-
lactation stages.
In our model, a significantly high level of circulating
estradiol remained in the transgenic mice at during the
later stages of lactation and decreased at the post-lactation
stage. Overall transgenic mice had higher estradiol levels
compared to WT mice. Estradiol is mainly produced by
the granulosa cells of the ovaries. Under normal physio-
logical conditions during pregnancy, circulating estrogen
increases and decreases during the lactation period. How-
ever, activation of Akt1 in the ovaries may increase the
proliferation of granulosa cells and lead to an increased
production of estradiol even in the later-lactation stage.
The higher circulating estrogen levels could further induce
higher AKT expression. The increased estradiol by the ac-
tivation of Akt1 in the ovaries could partially contribute to
the mammary tumorigenesis in the transgenic mice in our
model. Further studies examining mice with removed
ovaries need to be conducted for clarification. However,
the mammary tumorigenesis is more likely to be driven
by the expression of myr-Akt1 in the mammary glands
since we did not observe any ovarian or uterine cancers
in our model. In addition, local estrogen biosynthesis
such through Akt1 mediated aromatase expression in
the mammary glands or myr-Akt1 induction of prolactin
[22-24] could all contribute to mammary tumorigenesis.
High levels of prolactin have been associated with post-
menopausal breast cancer risk [25].
In our model, the transgene was maintained in C57BL6
mice which are genetically resistant to spontaneous mam-
mary tumor formation [15,26] in order to reduce back-
ground tumor activity in the wild-type mice. Therefore,
there is no spontaneous tumor formation in the wild-type
mice in this study.
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function has been examined in the postnatal stage of mice.
The activation of Akt1 or overexpression of total AKT
has been shown to delay mammary gland involution,
and to induce hyperplasia in similar Akt1-transgenic
mouse models [13,14]. In this study, we further examined
the role of Akt1 in mammary gland development from
pre-puberty, puberty, post-puberty (virgin), lactating to
post-lactation stages. Our data showed for the first time
that myr-Akt1 played a crucial role in the development of
the early adult mammary gland. Myr-Akt1+ mice had
mammary ductal outgrowths though the fat pads and ex-
tending alveolar epithelium during the post-puberty stage.
Consistent with other Akt1 transgenic models, a delayed
mammary gland involution was observed in our model as
well. The activation of Akt has been shown to accelerate
mammary tumorigenesis in MMTV-c-ErbB2 mice [27].
However, overexpression or activation of Akt1 in the
mammary glands alone is not enough to induce dysplasia
or neoplasia [28-31]. Activation of Akt1 induces oncogenic
transformation upon exposure to carcinogens [15]. Simi-
larly in our model, we demonstrated that exposure to the
carcinogen DMBA in transgenic mice with active Akt1
expression led to a significantly higher incidence of
mammary carcinoma. In addition we compared tumor
formation between transgenic mice and WT mice at
different ages.
Epidemiological studies have suggested that lactation
may have some protective effect on breast cancer risk in
humans [29-31]. Pregnancy and breast feeding have been
associated with a reduction of lifetime risk of breast cancer
among premenopausal women and women with family
history of breast cancer [32-34]. Mechanism studies using
mouse models suggest that the secretory mammae and
low rate of DNA synthesis in lactating mammary glands
may account for the elimination of carcinogens [35-37].
Studies have found that lactating mice were relatively re-
fractory to the effects of chemical carcinogens. Conversely,
the levels of estrogen and prolactin are increased during
pregnancy and lactation, and the high levels of estrogen
and prolactin could be associated with the development
of breast cancer [25,35]. Normally, the mammary gland
regresses to its pre-pregnancy status by a coordinated
process of apoptosis, remodeling, and inflammation
following pregnancy and lactation [38]. Activation of
Akt in mammary tissue could result in de-regulation of
the survival signal [31]. The normal mammary gland
involution after pregnancy and lactation could be
interrupted by active Akt1 expression in mammary tis-
sue. The irregular involution of the mammary gland
might increase susceptibility to carcinogen-induced
tumor formation. Data from our current study demon-
strated that the mice carrying the myr-Akt1 transgene
in the mammary glands had accelerated carcinogen-induced tumorigenesis during the virgin and post-
lactation stages. The protection against carcinogen-
induced mammary malignancy by lactation was eliminated
by expressing active Akt1 in the mammary tissues of
the transgenic mice. We found that there was no
DMBA induced tumor formation in the wild-type mice
throughout pregnancy and lactation. However, DMBA
induced mammary carcinomas were observed in 45.5%
of mice with the MMTVmyr-Akt1 transgene.
Our studied identified that the DMBA induced mam-
mary carcinomas in both transgenic and wild-type mice
were poorly differentiated. However, the tumor tissues
from transgenic mice had increased phosphorylated
Akt1 at ser473 and the tumors showed strong positive
expression of nuclear ERα. These findings are similar to
data reported from another group [15]. The tumors
from our model were also positive for EGFR expression.
Moreover, the tumors with low ERα expression concur-
rently had membranous expression of EGFR. ERα posi-
tive tumors with increased pAkt were associated with
strong cytoplasmic expression levels of EGFR. However,
the function of cytoplasmic expression of EGFR is un-
clear, although both membranous and cytoplasmic ex-
pression of EGFR has been reported before in cancers
such as pancreatic cancer. Tissues resected from pan-
creatic cancer patients with EGFR over-expression in
the cell membrane showed worse clinical outcomes
compared to patient tissues with low EGFR expression
[39]. Other studies demonstrated that EGFR expression
in the membrane is more strongly associated with malig-
nant tumors, while cytoplasmic EGFR expression is as-
sociated with normal cells or benign tumors [40,41].
Cytoplasmic EGFR over-expression was not signifi-
cantly associated with recurrence or survival in our
study.
It has been suggested that the activation of Akt might
cooperate with ERα activity in the development of mam-
mary tumors induced by DMBA [15]. The observations
from our current study are in agreement with this Akt -
ERα cooperation concept. In addition, our data implies
that the Akt-ERα cooperation may also have interactions
with the EGFR pathway. Cyclin D1 plays role in tumor cell
proliferation and is inversely correlated with tumor
size in human breast cancer [42]. Overexpression of
Cyclin D1 has been reported in 40% to 90% of invasive
breast cancers, while gene amplification is seen in
about 5–20% of tumors [43]. Increase in the protein
levels of Cyclin D1 is apparent in hyperplasias and is
further increased in malignancies [43,44]. Cyclin D1
has also been shown as an essential oncogenic intermedi-
ary for the Neu pathway by inducing mammary carcinoma
in transgenic mice [28,45]. In our model, we observed that
Cyclin D1 expression was higher in DMBA-induced myr-
Akt1 driven mammary carcinomas. However, Cyclin D1
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Akt1. It was also not essential for ER-positive tumor for-
mation since the levels of Cyclin D1 varied in tumors from
the transgenic mice. Similar observations were reported
by Blanco-Aparicio et al. [15].
In humans, more than 60% of breast cancer is ERα-
positive. Endocrine therapy, tamoxifen, is the most im-
portant systemic treatment of ER-positive breast cancer.
Unfortunately, patients with advanced ER-positive disease
eventually acquire resistance to tamoxifen treatment.
The MMTVmyr-Akt1 transgenic mice tumor formation
induced by carcinogens could mimic ER-positive human
breast cancer, as shown with increases in pAkt, Cyclin
D1, and EGFR. Furthermore, the transgenic mice in our
model exhibited characteristics of advanced ER-positive
mammary tumors with bone metastasis and increased
expression of the mesenchymal markers, twist and slug.
The data from this study showed that mammary tumors
with metastatic characteristics were associated with in-
creasing expression of twist and slug. The bone meta-
static lesions were also positive for ERα. Therefore, the
MMTV-myr-Akt1 transgenic mice could be useful for
exploring the underlying mechanisms of ER-positive
breast cancer acquiring resistance to tamoxifen and de-
veloping metastatic disease. EGFR-targeted therapy,
such as cetuximab and lapatinib in combination with
hormonal therapy may also be explored as methods to
overcome resistance. Patients with ERα-negative or
triple negative breast tumors frequently demonstrate
increased EGFR expression [46,47]. These patients are
more likely to have poor disease outcomes. Similar to
the aforementioned patient-based studies, we observed
that wild-type mice with mammary tumors from
DMBA induction showed an inverse relationship be-
tween nuclear expression of ERα and membranous
EGFR. Thus, the carcinogen-induced mammary tu-
mors from virgin mice in this study might also provide
an in vivo model for better understanding the etiology
and tumor biology of this type of breast cancer. From a
translational perspective, this will facilitate the design
of better target therapies for treating ER/HER2-/EGFR +
breast cancer.Conclusions
In summary, data from this study suggest that activation
of Akt1 in mammary tissue increases the risk of devel-
oping mammary tumors through carcinogen induction.
The breast cancer risk reduction associated with breast
feeding could be attenuated by the activation of Akt1 in
the mammary tissues. These data further affirm that our
MMTVmyr-Akt1 transgenic mouse is a valuable resource
for understanding the mechanisms of ER + breast cancer
development.Additional files
Additional file 1: Figure S1. The myr-Akt1 transgene and integration
of the transgene in transgenic mice. The CMV promoter in myr-Akt1 DNA
structure (#21-151, Upstate Biotechnology) was replaced by MMTV-LTR
(A) and the construct was digested and the fragment containing
MMTV-LTR promoter. Myr-Akt1 sequences and SV40 polyadenylation
signal were isolated and purified (B). (C) Shows the copy number
standard curve of qPCR. The simple linear regression standard curve was
built with logarithm transformed serial diluted myr-Akt1 plasmid DNA
(from 0.01 copies to 100 copies as described in methods) as an
independent variable, and qPCR Ct numbers as a dependent variable.
(D) DNA from transgenic mice and WT mice was amplified by q-PCR and
the numbers of transgene copies were estimated by the copy number
standard curve according to the numbers of Ct for each sample. Each
sample was triplicated and the bar indicates mean ± SD.
Additional file 2: Figure S2. Expression of Akt1 in wild-type (WT) and
transgenic mice (MMTV-myr-Akt1). Total RNA was extracted from
indicated organs of virgin (A) (9 weeks) and post-lactating (B) (16 weeks)
WT and transgenic mice. Three mice per genotype, per age group were
used for analysis. RT-PCR was performed with primers of Akt1 and β-actin.
Additional file 3: Figure S3. Growth of wild-type and transgenic mice.
Body weight of wild-type (WT) mice and transgenic mice (MMTV-myr-Akt1)
were measured from F3 generation. The body weight was monitored from
1 month old of MMTV-myr-Akt1+/+, MMTV-myr-Akt1+/- and WT mice until
6 months old. The body weight was mean of 6 to 8 per group and the
SD was less than 2 percent of mean.
Abbreviations
myr-Akt1: myristoylated-Akt1; DMBA: 7, 12 dimethyl-1,2-benzanthracene;
MMTV-LTR: Mouse Mammary Tumor Virus Long Terminal Repeat Promoter;
CMV: Cytomegalovirus immediate-early promoter; E2: Estradiol;
EGFR: Epidermal growth factor receptor; ER: Estrogen receptor;
PR: Progesterone receptor; HER2: Human Epidermal Growth Factor Receptor
2; EMT: Epithelial-mesenchymal transition.
Competing interests
The authors declare that they have no financial and non-financial competing
interests.
Authors’ contributions
JVV made contributions to conception, design, overall guidance for the
study, data interpretation and manuscript editing, revising for important
content; YW made contributions to design the transgene and experiments;
data acquisition, analysis, interpretation, and drafting the manuscript; JK
made contributions to acquisition, analysis of the data and also involve the
manuscript preparation, MS made contributions to the preparation of the
manuscript; and YE made contributions to analysis and interpretation of the
data, as well as preparation of the manuscript. All authors read and
approved the final version of the manuscript to be published.
Funding support
This work was supported by grants from NIH/NCI 1U54CA14393; U56
CA101599-01; CA15083-25S3; R25DK067015-01; Department-of-Defense
Breast Cancer Research Program grant BC043180, NIH-NIMHD U54MD007598,
NIH/NCATS CTSI UL1TR000124 to J.V. Vadgama and; NIH/NIMHD CRECD R25
MD007610 support to Y Wu.
Received: 29 October 2013 Accepted: 17 March 2014
Published: 17 April 2014
References
1. Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway
in human malignancy. Cell Signal 2001, 14:381–395.
2. Torres-Arzayus MI, de Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers
WR, Brown M: High tumor incidence and activation of the PI3K/AKT
pathway in transgenic mice define AIB1 as an oncogene. Canc Cell 2004,
6:263–274.
Wu et al. BMC Cancer 2014, 14:266 Page 13 of 13
http://www.biomedcentral.com/1471-2407/14/2663. Wang H, Xu Y, Fang Z, Chen S, Balk SP, Yuan X: Doxycycline regulated
induction of AKT in murine prostate drives proliferation independently of p27
cyclin dependent kinase inhibitor downregulation. PLoS One 2012, 7:e41330.
4. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester
CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs
S: Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J
Canc 2007, 120:796–805.
5. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H:
The antiapoptotic effect of fibroblast growth factor-2 is mediated through
nuclear factor kappaB activation induced via interaction between Akt and
IkappaB kinase-beta in breast cancer cells. Oncogene 2005, 24:5482–5491.
6. Mirza AM, Kohn AD, Roth RA, McMahon M: Oncogenic transformation of
cells by a conditionally active form of the protein kinase Akt/PKB. Cell
Growth Differ 2000, 11:279–292.
7. Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell
RG, Mueller SC, Ojeifo J, Chen WS, Hay M, Pestell RG: Akt1 governs breast
cancer progression in vivo. Proc Natl Acad Sci U S A 2007, 104:7438–7443.
8. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R,
Tsichlis PN, Nicosia SV, Cheng JQ: Akt1/PKBalpha kinase is frequently
elevated in human cancers and its constitutive activation is required for
oncogenic transformation in NIH3T3 cells. Am J Pathol 2001, 159:431–437.
9. Pérez-Tenorio G, Stål O, Southeast Sweden Breast Cancer Group: Activation
of Akt/PKB in breast cancer predicts a worse outcome among endocrine
treated patients. Br J Canc 2002, 86:540–545.
10. Wu Y, Mohamed H, Chillar R, Clayton S, Slamon D, Vadgama JV: Clinical
significance of Akt and HER2/neu overexpression in African-American
and Latina women with breast cancer. Breast Canc Res 2008, 10:1.
11. Tanner M, Kapanen AI, Junttila T: Characterization of a novel cell line
established from a patient with trastuzumab-resistant breast cancer.
Mol Canc Ther 2004, 3:1585–1592.
12. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV: FOXO1A is a target
for HER2-overexpressing breast tumors. Canc Res 2010, 70:5475–5485.
13. Schwertfeger KL, Richert MM, Anderson SM: Mammary gland involution is
delayed by activated Akt in transgenic mice. Mol Endo 2001, 15:867–881.
14. Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI: Delayed mammary gland
involution in MMTV-AKT1 transgenic mice. Oncogene 2002, 21:198–206.
15. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal J FM, Renner O, Carnero
A: Mice expressing myr-AKT1 in the mammary gland develop
carcinogen-induced ER-positive mammary tumors that mimic human
breast cancer. Carcinogenesis 2007, 28:584–594.
16. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, F.M. Leal J, Renner O, Carnero
A: Exploring the gain of function contribution of AKT to mammary
tumorigenesis in mouse model. PLoS One 2010, 5:e9305.
17. Yuan JS, Burris J, Stewart NR, Mentewab A, Stewart CN: Statistical tools for
transgene copy number estimation based on real-time PCR. BMC
Bioinforma 2007, 8:S6.
18. Mitrečić D, Huzak M, Ćurlin M, Gajović S: An improved method for
determination of gene copy numbers in transgenic mice by serial
dilution curves obtained by real-time quantitative PCR assay. J Biochem
Biophys Methods 2005, 64:83–98.
19. Hennighausen L, Robinson GW: Information networks in the mammary
gland. Nat Rev Mol Cell Biol 2005, 6:715–725.
20. Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable
signaling mechanisms that create it. Dev Dyn 2005, 233:706–720.
21. Pattengale PK, Stewart TA, Leder A, Sinn E, Muller W, Tepler I, Schmidt E, Leder
P: Animal models of human disease. Pathology and molecular biology of
spontaneous neoplasms occurring in transgenic mice carrying and
expressing activated cellular oncogenes. Am J Pathol 1989, 135:39–61.
22. Chen CC, Stairs DB, Boxer RB, Belka GK, Horseman ND, Alvarez JV, Chodosh
LA: Autocrine prolactin induced by the Pten-Akt pathway is required for
lactation initiation and provides a direct link between the Akt and Stat5
pathway. Gene Dev 2012, 26:2154–2168.
23. Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, Jones M:
Local estrogen biosynthesis in males and females. Endocr Relat Canc
1999, 6:131–137.
24. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, Jeong HG: Bisphenol
A-induced aromatase activation is mediated by cyclooxygenase-2
up-regulation in rat testicular leydig cells. Toxicol Lett 2010, 193:200–208.
25. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson
SE: A 20-year prospective study of plasma prolactin as a risk marker of
breast cancer development. Canc Res 2013, 73:4810–4819.26. Turusov VS, Morozova OV, Samoilov DV: Estrogen modification of 1,2
dimethylhydrazine carcinogenesis in C3HA mice. Canc Lett 1994, 83:51–58.
27. Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM: Activated Akt1
accelerates MMTV-c-EebB2 mammary tumorigenesis in mice without
activation of ErbB3. Breast Canc Res 2008, 10:R70.
28. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of
MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic
action of oncogene in vivo. Cell 1987, 49:465–475.
29. Hutchinson JN, Muller WJ: Transgenic mouse models of human breast
cancer. Oncogene 2000, 19:6130–6137.
30. Henry MD, Triplett AA, Oh KB, Smith GH, Wagner KU: Parity-induced
mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic
mice. Oncogene 2004, 23:6980–6985.
31. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt
(protein kinase B) in mammary epithelium provides a critical cell survival
signal required for tumor progression. Mol Cell Biol 2001, 21:2203–2212.
32. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Clapp
RW, Burke KP, Willett WC, MacMahon B: Lactation and a reduced risk of
premenopausal breast cancer. N Engl J Med 1994, 330:81–87.
33. Freudenheim JL, Marshall JR, Vena JE, Moysich KB, Muti P, Laughlin R, Nemoto
T, Graham S: Lactation history and breast cancer risk. Am J Epidemiol 1997,
146:11.
34. Stuebe AM, Willett WC, Xue F, Michels KB: Lactation and incidence of
premenopausal breast cancer. A longitudinal study. Arch Intern Med 2009,
169:1364–1371.
35. Welsch CW, Nagasawa H: Prolactin and murine mammary tumorigenesis:
a review. Canc Res 1977, 37:951–963.
36. Banerjee MR, Wagner JE, Kinder DL: DNA synthesis in the absence of cell
reproduction during functional differentiation of mouse mammary
gland. Life Sci 1971, 10:867–877.
37. Banerjee MR, Wagner JE: Variable duration of DNA synthesis in mammary
gland cells during pregnancy and lactation of C3H/He mouse. J Cell
Physiol 1967, 69:13342.
38. Watson CL: Post-lactational mammary gland regression: molecular basis
and implications for breast cancer. Expet Rev Mol Med 2006, 8:1–15.
39. Mahipal A, Mcdonald MJ, Witkiewicz A, Carr BI: Cell membrane and
cytoplasmic epidermal growth factor receptor expression in pancreatic
ductal adenocarcinoma. Med Oncol 2012, 29:134–139.
40. Pu YS, Huang CY, Kuo YZ, Kang WY, Liu GY, Huang AM, Yu HJ, Lai MK,
Huang SP, Wu WJ, Chiou SJ, Hour TC: Characterization of membranous
and cytoplasmic EGFR expression in human normal renal cortex and
renal cell carcinoma. J Biomed Sci 2009, 16:82.
41. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA,
Hochhauser D: Interaction of the epidermal growth factor receptor and
the DNA-dependent protein kinase pathway following gefitinib treat-
ment. Mol Canc Ther 2006, 5:209–218.
42. Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, Harkonen P,
Lamb R, Landberg G: Down-regulation of the oncogene cyclin D1
increases migratory capacity in breast cancer and is linked to
unfavorable prognostic features. Am J Pathol 2010, 177:2886–2897.
43. Roy PG, Thompson AM: Cyclin D1 and breast cancer. Rev Breast 2006,
15:718–727.
44. Sutherland RL, Musgrove EA: Cyclin D1 and mammary carcinoma: new
insights from transgenic mouse models. Breast Canc Res 2002, 4:14–17.
45. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look
AT, Kung AL, Boehmer HV, Sicinski P: The Requirement for Cyclin D
Function in Tumor Maintenance. Canc Cell 2012, 22:438–451.
46. Siziopikou KP, Cobleigh M: The basal subtype of breast carcinomas may
represent the group of breast tumors that could benefit from EGFR-
targeted therapies. Breast 2007, 16:104–107.
47. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM,
Gilks CB, van de Rijn M, Perou CM: Immunohitochemical and clinical
characterization of the basal-like subtype of invasive breast carcinoma.
Clin Canc Res 2004, 10:5367–5374.
doi:10.1186/1471-2407-14-266
Cite this article as: Wu et al.: Activation of Akt1 accelerates carcinogen-
induced tumorigenesis in mammary gland of virgin and post-lactating
transgenic mice. BMC Cancer 2014 14:266.
